Skip to main content
. 2020 Sep 11;7(6):3401–3407. doi: 10.1002/ehf2.12891

Figure 1.

Figure 1

Effects on glycated haemoglobin (HbA1c; top panel), systolic blood pressure (SBP; middle panel), and body weight (lower panel) with empagliflozin vs. placebo during first year of treatment in patients with (on the left) or without (on the right) heart failure. Error bars represent 95% confidence intervals.